The Binary Classification of Protein Kinases

References

• Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science. 2002;298(5600):1912–1934. doi:10.1126/science.1075762
   Google Scholar
• Ardito F, Giuliani M, Perrone D, Troiano G, Lo Muzio L. The crucial role of protein phosphorylation in cell signaling and its use as targeted therapy (review). Int J Mol Med. 2017;40(2):271–280. doi:10.3892/ijmm.2017.3036
   Google Scholar
• Sacco F, Perfetto L, Castagnoli L, Cesareni G. The human phosphatase interactome: an intricate family portrait. FEBS Lett. 2012;586(17):2732–2739. doi:10.1016/j.febslet.2012.05.008
   Google Scholar
• Ferguson FM, Gray NS. Kinase inhibitors: the road ahead. Nat Rev Drug Discov. 2018;17(5):353–377. doi:10.1038/nrd.2018.21
   Google Scholar
• Szilveszter KP, Németh T, Mócsai A. Tyrosine kinases in autoimmune and inflammatory skin diseases. Front Immunol. 2019;10:1862. doi:10.3389/fimmu.2019.01862
   Google Scholar
• Siasos G, Tousoulis D, Siasou Z, Stefanadis C, Papavassiliou AG. Shear stress, protein kinases and atherosclerosis. Curr Med Chem. 2007;14(14):1567–1572. doi:10.2174/092986707780831087
   Google Scholar
• Kinase-disease association/cell signaling technology. Available from: https://www.cellsignal.com/contents/resources-reference-tables/kinase-disease-associations/science-tables-kinase-disease. Accessed February 26, 2021.
   Google Scholar
• Elkoshi Z. The binary classification of chronic diseases. J Inflamm Res. 2019;12:319–333. doi:10.2147/JIR.S227279
   Google Scholar
• Elkoshi Z. “High treg” inflammations promote (most) non-hematologic cancers while “low treg” inflammations promote lymphoid cancers. J Inflamm Res. 2020;13:209–221. doi:10.2147/JIR.S249384
   PubMed Web of Science ®Google Scholar
• Bagnardi V, Rota M, Botteri E, et al. Alcohol consumption and site-specific cancer risk: a comprehensive dose-response meta-analysis. Br J Cancer. 2015;112(3):580–593. doi:10.1038/bjc.2014.579
   PubMed Web of Science ®Google Scholar
• Carlé A, Pedersen IB, Knudsen N, et al. Moderate alcohol consumption may protect against overt autoimmune hypothyroidism: a population-based case-control study. Eur J Endocrinol. 2012;167(4):483–490. doi:10.1530/EJE-12-0356
   PubMed Web of Science ®Google Scholar
• Zhang X, Fang X, Gao Z, et al. Axitinib, a selective inhibitor of vascular endothelial growth factor receptor, exerts an anticancer effect in melanoma through promoting antitumor immunity. Anticancer Drugs. 2014;25(2):204–211. doi:10.1097/CAD.0000000000000033
   PubMed Web of Science ®Google Scholar
• Napoletano C, Ruscito I, Bellati F, et al. Bevacizumab-based chemotherapy triggers immunological effects in responding multi-treated recurrent ovarian cancer patients by favoring the recruitment of effector T cell subsets. J Clin Med. 2019;8(3):380. doi:10.3390/jcm8030380
   PubMed Web of Science ®Google Scholar
• Bergerot P, Lamb P, Wang E, Pal SK. Cabozantinib in combination with immunotherapy for advanced renal cell carcinoma and urothelial carcinoma: rationale and clinical evidence. Mol Cancer Ther. 2019;18(12):2185–2193. doi:10.1158/1535-7163.MCT-18-1399
   PubMed Web of Science ®Google Scholar
• Kwilas AR, Ardiani A, Donahue RN, Aftab DT, Hodge JW. Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine. J Transl Med. 2014;12(1):294. doi:10.1186/s12967-014-0294-y
   PubMed Web of Science ®Google Scholar
• Jie HB, Schuler PJ, Lee SC, et al. CTLA-4+ regulatory T cells increased in cetuximab-treated head and neck cancer patients suppress NK cell cytotoxicity and correlate with poor prognosis. Cancer Res. 2015;75(11):2200–2210. doi:10.1158/0008-5472.CAN-14-2788
   PubMed Web of Science ®Google Scholar
• Liu P, Zhao L, Kepp O, Kroemer G. Crizotinib - a tyrosine kinase inhibitor that stimulates immunogenic cell death. Oncoimmunology. 2019;8(7):1596652. doi:10.1080/2162402X.2019.1596652
   PubMed Web of Science ®Google Scholar
• Fei F, Yu Y, Schmitt A, et al. Dasatinib inhibits the proliferation and function of CD4+CD25+ regulatory T cells. Br J Haematol. 2009;144(2):195–205. doi:10.1111/j.1365-2141.2008.07433.x
   PubMed Web of Science ®Google Scholar
• Palakurthi S, Kuraguchi M, Zacharek SJ, et al. The combined effect of FGFR inhibition and PD-1 blockade promotes tumor-intrinsic induction of antitumor immunity. Cancer Immunol Res. 2019;7(9):1457–1471. doi:10.1158/2326-6066.CIR-18-0595
   PubMed Web of Science ®Google Scholar
• Ayeni D, Miller B, Kuhlmann A, et al. Tumor regression mediated by oncogene withdrawal or erlotinib stimulates infiltration of inflammatory immune cells in EGFR mutant lung tumors. J Immunother Cancer. 2019;7(1):172. doi:10.1186/s40425-019-0643-8
   PubMedGoogle Scholar
• Wang S, Zhang Y, Wang Y, et al. Amphiregulin confers regulatory T cell suppressive function and tumor invasion via the EGFR/GSK-3β/Foxp3 axis. J Biol Chem. 2016;291(40):21085–21095. doi:10.1074/jbc.M116.717892
   PubMed Web of Science ®Google Scholar
• Podhorecka M, Goracy A, Szymczyk A, et al. Changes in T-cell subpopulations and cytokine network during early period of ibrutinib therapy in chronic lymphocytic leukemia patients: the significant decrease in T regulatory cells number. Oncotarget. 2017;8(21):34661–34669. doi:10.18632/oncotarget.16148
   PubMedGoogle Scholar
• Larmonier N, Janikashvili N, LaCasse CJ, et al. Imatinib mesylate inhibits CD4+ CD25+ regulatory T cell activity and enhances active immunotherapy against BCR-ABL- tumors. J Immunol. 2008;181(10):6955–6963. doi:10.4049/jimmunol.181.10.6955
   PubMed Web of Science ®Google Scholar
• Kimura T, Kato Y, Ozawa Y, et al. Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model. Cancer Sci. 2018;109(12):3993–4002. doi:10.1111/cas.13806
   PubMed Web of Science ®Google Scholar
• Lu Z, Xu N, Zhou X, et al. Therapeutic immune monitoring of CD4+CD25+ T cells in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. Oncol Lett. 2017;14(2):1363–1372. doi:10.3892/ol.2017.6294
   PubMed Web of Science ®Google Scholar
• Wang X, Shan S, Semba T, et al. Abstract 4492: humanized anti-EGFR antibody panitumumab inhibits tumor growth of inflammatory breast cancer by inducing antitumor immunity. Cancer Res. 2019;79(13 Supplement):4492. doi:10.1158/1538-7445.AM2019-4492
   Web of Science ®Google Scholar
• Verzoni E, De Cecco L, Dugo M, et al. Broad immunomodulating effect of first-line pazopanib in metastatic renal cell carcinoma patients. Ann Oncol. 2017:28. doi:10.1093/annonc/mdx371.043.
   Google Scholar
• Busse A, Asemissen AM, Nonnenmacher A, et al. Immunomodulatory effects of sorafenib on peripheral immune effector cells in metastatic renal cell carcinoma. Eur J Cancer. 2011;47(5):690–696. doi:10.1016/j.ejca.2010.11.021
   PubMed Web of Science ®Google Scholar
• Stehle F, Schulz K, Fahldieck C, et al. Reduced immunosuppressive properties of axitinib in comparison with other tyrosine kinase inhibitors. J Biol Chem. 2013;288(23):16334–16347. doi:10.1074/jbc.M112.437962
   PubMed Web of Science ®Google Scholar
• Finke JH, Rini B, Ireland J, et al. Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res. 2008;14(20):6674–6682. doi:10.1158/1078-0432.CCR-07-5212
   PubMed Web of Science ®Google Scholar
• Salas RN, Finke JH, Rini B. The intersection of sunitinib with the immunosuppressive microenvironment of renal cell carcinoma: implications for future therapeutics. Target Oncol. 2007;2(4):225–234. doi:10.1007/s11523-007-0064-3
   Web of Science ®Google Scholar
• Ko JS, Zea AH, Rini BI, et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res. 2009;15(6):2148–2157. doi:10.1158/1078-0432.CCR-08-1332
   PubMed Web of Science ®Google Scholar
• Horlock C, Stott B, Dyson PJ, et al. The effects of trastuzumab on the CD4+CD25+FoxP3+ and CD4+IL17A+ T-cell axis in patients with breast cancer. Br J Cancer. 2009;100(7):1061–1067. doi:10.1038/sj.bjc.6604963
   PubMed Web of Science ®Google Scholar
• Steinberg SM, Zhang P, Malik BT, et al. BRAF inhibition alleviates immune suppression in murine autochthonous melanoma. Cancer Immunol Res. 2014;2(11):1044–1050. doi:10.1158/2326-6066.CIR-14-0074
   PubMed Web of Science ®Google Scholar
• Ghoreschi K, Laurence A, O’Shea JJ. Janus kinases in immune cell signaling. Immunol Rev. 2009;228(1):273–287. doi:10.1111/j.1600-065X.2008.00754.x
   PubMed Web of Science ®Google Scholar
• Iamsawat S, Daenthanasanmak A, Voss JH, et al. Stabilization of Foxp3 by targeting JAK2 enhances efficacy of CD8 induced regulatory T cells in the prevention of graft-versus-host disease. J Immunol. 2018;201(9):2812–2823. doi:10.4049/jimmunol.1800793
   PubMed Web of Science ®Google Scholar
• Barbui T, Carobbio A, Finazzi G, et al. Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3. Haematologica. 2011;96(2):315–318. doi:10.3324/haematol.2010.031070
   PubMed Web of Science ®Google Scholar
• Hasselbalch HC, Bjørn ME. MPNs as inflammatory diseases: the evidence, consequences, and perspectives. Mediators Inflamm. 2015;2015:102476. doi:10.1155/2015/102476
   PubMed Web of Science ®Google Scholar
• Fragoulis GE, McInnes IB, Siebert S. JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis. Rheumatology (Oxford). 2019;58(Suppl1):i43–i54. doi:10.1093/rheumatology/key276
   PubMedGoogle Scholar
• Pei H, He L, Shao M, et al. Discovery of a highly selective JAK3 inhibitor for the treatment of rheumatoid arthritis. Sci Rep. 2018;8(1):5273. doi:10.1038/s41598-018-23569-y
   PubMedGoogle Scholar
• Fleischmann RM, Damjanov NS, Kivitz AJ, Legedza A, Hoock T, Kinnman N. A randomized, double-blind, placebo-controlled, twelve-week, dose-ranging study of decernotinib, an oral selective JAK-3 inhibitor, as monotherapy in patients with active rheumatoid arthritis. Arthritis Rheumatol. 2015;67(2):334–343. doi:10.1002/art.38949
   PubMed Web of Science ®Google Scholar
• Shimoda K, Kato K, Aoki K, et al. Tyk2 plays a restricted role in IFN alpha signaling, although it is required for IL-12-mediated T cell function. Immunity. 2000;13(4):561–571. doi:10.1016/s1074-7613(00)00055-8
   PubMed Web of Science ®Google Scholar
• Ishizaki M, Akimoto T, Muromoto R, et al. Involvement of tyrosine kinase-2 in both the IL-12/Th1 and IL-23/Th17 axes in vivo. J Immunol. 2011;187(1):181–189. doi:10.4049/jimmunol.1003244
   PubMed Web of Science ®Google Scholar
• Banerjee S, Biehl A, Gadina M, Hasni S, Schwartz DM. JAK-STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects [published correction appears in drugs.;77 (8):939][published correction appears in drugs. 2017 Jun 12]. Drugs. 2017;77(5):521–546. doi:10.1007/s40265-017-0701-9
   PubMed Web of Science ®Google Scholar
• Rother N. Disturbed T cell signaling and altered Th17 and regulatory T cell subsets in the pathogenesis of systemic lupus erythematosus. Front Immunol. 2015;6:610. doi:10.3389/fimmu.2015.00610
   PubMed Web of Science ®Google Scholar
• Bussel J, Arnold DM, Grossbard E, et al. Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: results of two Phase 3, randomized, placebo-controlled trials. Am J Hematol. 2018;93(7):921–930. doi:10.1002/ajh.25125
   PubMed Web of Science ®Google Scholar
• Newland A, Lee EJ, McDonald V, Bussel JB. Fostamatinib for persistent/chronic adult immune thrombocytopenia. Immunotherapy. 2018;10(1):9–25. doi:10.2217/imt-2017-0097
   PubMed Web of Science ®Google Scholar
• Keohane C, Kordasti S, Seidl T, et al. JAK inhibition induces silencing of T Helper cytokine secretion and a profound reduction in T regulatory cells. Br J Haematol. 2015;171(1):60–73. doi:10.1111/bjh.13519
   PubMed Web of Science ®Google Scholar
• Sewgobind VD, Quaedackers ME, van der Laan LJ, et al. The Jak inhibitor CP-690550 preserves the function of CD4CD25FoxP3 regulatory T cells and inhibits effector T cells. Am J Transplant. 2010;10(8):1785–1795. doi:10.1111/j.1600-6143.2010.03200.x
   PubMed Web of Science ®Google Scholar
• Meyer A, Wittekind PS, Kotschenreuther K, et al. Regulatory T cell frequencies in patients with rheumatoid arthritis are increased by conventional and biological DMARDs but not by JAK inhibitors. Ann Rheum Dis. 2019:annrheumdis-2019-216576. doi:10.1136/annrheumdis-2019-216576.
   Web of Science ®Google Scholar
• Alzahrani KS, Nadeem A, Ahmad SF, et al. Inhibition of spleen tyrosine kinase attenuates psoriasis-like inflammation in mice through blockade of dendritic cell-Th17 inflammation axis. Biomed Pharmacother. 2019;111:347–358. doi:10.1016/j.biopha.2018.12.060
   PubMed Web of Science ®Google Scholar
• Park JS, Lee J, Lim MA, et al. JAK2-STAT3 blockade by AG490 suppresses autoimmune arthritis in mice via reciprocal regulation of regulatory T cells and Th17 cells. J Immunol. 2014;192(9):4417–4424. doi:10.4049/jimmunol.1300514
   PubMed Web of Science ®Google Scholar
• Tanaka Y, McInnes IB, Taylor PC, et al. Characterization and changes of lymphocyte subsets in baricitinib-treated patients with rheumatoid arthritis: an integrated analysis. Arthritis Rheumatol. 2018;70(12):1923–1932. doi:10.1002/art.40680
   PubMed Web of Science ®Google Scholar
• Jasiecka-Mikolajczyk A, Socha P, Jaroszewski JJ, Maslanka T. Oclacitinib induces Foxp3 expression in CD4+ T cells under activation conditions. J Immunol. 2020;204(1 Supplement):92.
   Web of Science ®Google Scholar
• Betts BC, Bastian D, Iamsawat S, et al. Targeting JAK2 reduces GVHD and xenograft rejection through regulation of T cell differentiation. Proc Natl Acad Sci U S A. 2018;115(7):1582–1587. doi:10.1073/pnas.1712452115
   PubMed Web of Science ®Google Scholar
• Spoerl S, Mathew NR, Bscheider M, et al. Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease. Blood. 2014;123(24):3832–3842. doi:10.1182/blood-2013-12-543736
   PubMed Web of Science ®Google Scholar
• Parampalli Yajnanarayana S, Stübig T, Cornez I, et al. JAK1/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms. Br J Haematol. 2015;169(6):824–833. doi:10.1111/bjh.13373
   PubMed Web of Science ®Google Scholar
• Massa M, Rosti V, Campanelli R, Fois G, Barosi G. Rapid and long-lasting decrease of T-regulatory cells in patients with myelofibrosis treated with ruxolitinib. Leukemia. 2014;28(2):449–451. doi:10.1038/leu.2013.296
   PubMed Web of Science ®Google Scholar
• Virtanen T, Haikarainen T, Raivola J, Silvennoinen O. Selective JAKinibs: prospects in inflammatory and autoimmune diseases. BioDrugs. 2019;33(1):15–32. doi:10.1007/s40259-019-00333-w
   PubMed Web of Science ®Google Scholar
• Sigismund S, Avanzato D, Lanzetti L. Emerging functions of the EGFR in cancer. Mol Oncol. 2018;12(1):3–20. doi:10.1002/1878-0261.12155
   PubMed Web of Science ®Google Scholar
• Zaiss DM, van Loosdregt J, Gorlani A, et al. Amphiregulin enhances regulatory T cell-suppressive function via the epidermal growth factor receptor. Immunity. 2013;38(2):275–284. doi:10.1016/j.immuni.2012.09.023
   PubMed Web of Science ®Google Scholar
• Apte RS, Chen DS, Ferrara N. VEGF in signaling and disease: beyond discovery and development. Cell. 2019;176(6):1248–1264. doi:10.1016/j.cell.2019.01.021
   PubMed Web of Science ®Google Scholar
• Zhu P, Hu C, Hui K, Jiang X. The role and significance of VEGFR2+ regulatory T cells in tumor immunity. Onco Targets Ther. 2017;10:4315–4319. doi:10.2147/OTT.S142085
   PubMed Web of Science ®Google Scholar
• Farooqi AA, Siddik ZH. Platelet-derived growth factor (PDGF) signalling in cancer: rapidly emerging signalling landscape. Cell Biochem Funct. 2015;33(5):257–265. doi:10.1002/cbf.3120
   PubMed Web of Science ®Google Scholar
• Agrawal S, Ganguly S, Hajian P, Cao JN, Agrawal A. PDGF upregulates CLEC-2 to induce T regulatory cells. Oncotarget. 2015;6(30):28621–28632. doi:10.18632/oncotarget.5765
   PubMedGoogle Scholar
• Croce L, Coperchini F, Magri F, Chiovato L, Rotondi M. The multifaceted anti-cancer effects of BRAF-inhibitors. Oncotarget. 2019;10(61):6623–6640. doi:10.18632/oncotarget.27304
   PubMedGoogle Scholar
• Shabaneh TB, Molodtsov AK, Steinberg SM, et al. Oncogenic BRAFV600E governs regulatory T-cell recruitment during melanoma tumorigenesis. Cancer Res. 2018;78(17):5038–5049. doi:10.1158/0008-5472.CAN-18-0365
   PubMed Web of Science ®Google Scholar
• Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949–954. doi:10.1038/nature00766
   PubMed Web of Science ®Google Scholar
• Kang ZJ, Liu YF, Xu LZ, et al. The Philadelphia chromosome in leukemogenesis. Chin J Cancer. 2016;35:48. doi:10.1186/s40880-016-0108-0
   PubMed Web of Science ®Google Scholar
• Manlove LS, Berquam-Vrieze KE, Pauken KE, Williams RT, Jenkins MK, Farrar MA. Adaptive immunity to leukemia is inhibited by cross-reactive induced regulatory T cells. J Immunol. 2015;195(8):4028–4037. doi:10.4049/jimmunol.1501291
   PubMed Web of Science ®Google Scholar
• Buckner JH. Mechanisms of impaired regulation by CD4(+)CD25(+)FOXP3(+) regulatory T cells in human autoimmune diseases. Nat Rev Immunol. 2010;10(12):849–859. doi:10.1038/nri2889
   PubMed Web of Science ®Google Scholar
• Cai Y, Fleming C, Yan J. New insights of T cells in the pathogenesis of psoriasis. Cell Mol Immunol. 2012;9(4):302–309. doi:10.1038/cmi.2012.15
   PubMed Web of Science ®Google Scholar
• Federici M, Giustizieri ML, Scarponi C, Girolomoni G, Albanesi C. Impaired IFN-gamma-dependent inflammatory responses in human keratinocytes overexpressing the suppressor of cytokine signaling 1. J Immunol. 2002;169(1):434–442. doi:10.4049/jimmunol.169.1.434
   PubMed Web of Science ®Google Scholar
• Morelli M, Scarponi C, Mercurio L, et al. Selective immunomodulation of inflammatory pathways in keratinocytes by the janus kinase (JAK) inhibitor tofacitinib: implications for the employment of JAK-targeting drugs in psoriasis. J Immunol Res. 2018;2018:7897263. doi:10.1155/2018/7897263
   PubMed Web of Science ®Google Scholar
• Jones DS, Jenney AP, Swantek JL, Burke JM, Lauffenburger DA, Sorger PK. Profiling drugs for rheumatoid arthritis that inhibit synovial fibroblast activation. Nat Chem Biol. 2017;13(1):38–45. doi:10.1038/nchembio.2211
   PubMed Web of Science ®Google Scholar
• Vainchenker W, Leroy E, Gilles L, Marty C, Plo I, Constantinescu SN. JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders. F1000Res. 2018;7:82. doi:10.12688/f1000research.13167.1
   PubMedGoogle Scholar
• Liotta F, Gacci M, Frosali F, et al. Frequency of regulatory T cells in peripheral blood and in tumour-infiltrating lymphocytes correlates with poor prognosis in renal cell carcinoma. BJU Int. 2011;107(9):1500–1506. doi:10.1111/j.1464-410X.2010.09555.x
   PubMed Web of Science ®Google Scholar
• Medicines.org.uk; Pfizer Limited; 2021. Inlyta 5 mg film coated tablet; Summary of Product Characteristics. Available from: https://www.medicines.org.uk/emc/product/7948. Accessed 4 March 2021. 
   Google Scholar
• Medicines.org.uk; Roche Products Limited; 2021. Avastin 25mg/ml concentrate for solution for infusion; Summary of Product Characteristics. Available from: https://www.medicines.org.uk/emc/product/3885. Accessed 4 March 2021.
   Google Scholar
• Wijarnpreecha K, Nissaisorakarn P, Sornprom S, et al. Hepatitis C infection and renal cell carcinoma: a systematic review and meta-analysis. World J Gastrointest Pathophysiol. 2016;7(4):314–319. doi:10.4291/wjgp.v7.i4.314
   PubMedGoogle Scholar
• Farhadi A, Behzad-Behbahani A, Geramizadeh B, et al. Presence of oncogenic viruses (EBV, HHV-6, BKV and JCV) DNA sequences in renal cell carcinoma. Int J Infect Dis. 2012;16(1):e80. doi:10.1016/j.ijid.2012.05.193
   Google Scholar
• Shimakage M, Kawahara K, Harada S, Sasagawa T, Shinka T, Oka T. Expression of Epstein-Barr virus in renal cell carcinoma. Oncol Rep. 2007;18(1):41–46.
   PubMed Web of Science ®Google Scholar
• Heidegger I, Borena W, Pichler R. The role of human papilloma virus in urological malignancies. Anticancer Res. 2015;35(5):2513–2519.
   PubMed Web of Science ®Google Scholar
• Liu C, Wu S, Meng X, et al. Predictive value of peripheral regulatory T cells in non-small cell lung cancer patients undergoing radiotherapy. Oncotarget. 2017;8(26):43427–43438. doi:10.18632/oncotarget.15238
   PubMedGoogle Scholar
• Shimizu K, Nakata M, Hirami Y, Yukawa T, Maeda A, Tanemoto K. Tumor-infiltrating Foxp3+ regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer. J Thorac Oncol. 2010;5(5):585–590. doi:10.1097/JTO.0b013e3181d60fd7
   PubMed Web of Science ®Google Scholar
• Zhu QG, Zhang SM, Ding XX, He B, Zhang HQ. Driver genes in non-small cell lung cancer: characteristics, detection methods, and targeted therapies. Oncotarget. 2017;8(34):57680–57692. doi:10.18632/oncotarget.17016
   PubMedGoogle Scholar
• Liu Y, O’Brien JL, Ajami NJ, et al. Lung tissue microbial profile in lung cancer is distinct from emphysema. Am J Cancer Res. 2018;8(9):1775–1787.
   PubMed Web of Science ®Google Scholar
• O’Mahony C, Scully P, O’Mahony D, et al. Commensal-induced regulatory T cells mediate protection against pathogen-stimulated NF-kappaB activation. PLoS Pathog. 2008;4(8):e1000112. doi:10.1371/journal.ppat.1000112
   PubMed Web of Science ®Google Scholar
• Mertens J, Fabri M, Zingarelli A, et al. Streptococcus pneumoniae serotype 1 capsular polysaccharide induces CD8CD28 regulatory T lymphocytes by TCR crosslinking. PLoS Pathog. 2009;5(9):e1000596. doi:10.1371/journal.ppat.1000596
   PubMed Web of Science ®Google Scholar
• Larsen JM. The immune response to Prevotella bacteria in chronic inflammatory disease. Immunology. 2017;151(4):363–374. doi:10.1111/imm.12760
   PubMed Web of Science ®Google Scholar
• Mangalam A, Shahi SK, Luckey D, et al. Human gut-derived commensal bacteria suppress CNS inflammatory and demyelinating disease. Cell Rep. 2017;20(6):1269–1277. doi:10.1016/j.celrep.2017.07.031
   PubMed Web of Science ®Google Scholar
• Robinson LA, Jaing CJ, Pierce Campbell C, et al. Molecular evidence of viral DNA in non-small cell lung cancer and non-neoplastic lung. Br J Cancer. 2016;115(4):497–504. doi:10.1038/bjc.2016.213
   PubMed Web of Science ®Google Scholar
• Kheir F, Zhao M, Strong MJ, et al. Detection of Epstein-Barr virus infection in non-small cell lung cancer. Cancers (Basel). 2019;11(6):759. doi:10.3390/cancers11060759
   PubMed Web of Science ®Google Scholar
• Landtblom AR, Andersson TM, Dickman PW, et al. Risk of infections in patients with myeloproliferative neoplasms-a population-based cohort study of 8363 patients [published online ahead of print, 2020 Jun 16]. Leukemia. 2020. doi:10.1038/s41375-020-0909-7.
   PubMed Web of Science ®Google Scholar
• Ruan S, Tate C, Lee JJ, Ritter T, Kolls JK, Shellito JE. Local delivery of the viral interleukin-10 gene suppresses tissue inflammation in murine Pneumocystis carinii infection. Infect Immun. 2002;70(11):6107–6113. doi:10.1128/iai.70.11.6107-6113.2002
   PubMed Web of Science ®Google Scholar
• Wright TW, Gigliotti F, Finkelstein JN, McBride JT, An CL, Harmsen AG. Immune-mediated inflammation directly impairs pulmonary function, contributing to the pathogenesis of Pneumocystis carinii pneumonia. J Clin Invest. 1999;104(9):1307–1317. doi:10.1172/JCI6688
   PubMed Web of Science ®Google Scholar
• Shrivastava S, TrehanPati N, Patra S, et al. Increased regulatory T cells and impaired functions of circulating CD8 T lymphocytes is associated with viral persistence in Hepatitis B virus-positive newborns. J Viral Hepat. 2013;20(8):582–591. doi:10.1111/jvh.12078
   PubMed Web of Science ®Google Scholar
• Kolata JB, Kühbandner I, Link C, et al. The fall of a dogma? Unexpected high T-cell memory response to Staphylococcus aureus in humans. J Infect Dis. 2015;212(5):830–838. doi:10.1093/infdis/jiv128
   PubMed Web of Science ®Google Scholar
• Frodermann V, Chau TA, Sayedyahossein S, Toth JM, Heinrichs DE, Madrenas J. A modulatory interleukin-10 response to staphylococcal peptidoglycan prevents Th1/Th17 adaptive immunity to Staphylococcus aureus. J Infect Dis. 2011;204(2):253–262. doi:10.1093/infdis/jir276
   PubMed Web of Science ®Google Scholar
• Ferraro A, Buonocore SM, Auquier P, et al. Role and plasticity of Th1 and Th17 responses in immunity to Staphylococcus aureus. Hum Vaccin Immunother. 2019;15(12):2980–2992. doi:10.1080/21645515.2019.1613126
   PubMed Web of Science ®Google Scholar
• Rose WE, Shukla SK, Berti AD, et al. Increased endovascular staphylococcus aureus inoculum is the link between elevated serum interleukin 10 concentrations and mortality in patients with bacteremia [published correction appears in clin infect dis. 2017 Oct 15;65(8):1431–1433]. Clin Infect Dis. 2017;64(10):1406–1412. doi:10.1093/cid/cix157
   PubMed Web of Science ®Google Scholar
• Zhang J, Zhu Z, Zuo X, et al. The role of NTHi colonization and infection in the pathogenesis of neutrophilic asthma. Respir Res. 2020;21(1):170. doi:10.1186/s12931-020-01438-5
   PubMed Web of Science ®Google Scholar
• Essilfie AT, Simpson JL, Horvat JC, et al. Haemophilus influenzae infection drives IL-17-mediated neutrophilic allergic airways disease. PLoS Pathog. 2011;7(10):e1002244. doi:10.1371/journal.ppat.1002244
   PubMed Web of Science ®Google Scholar
• Guan X, Lu Y, Wang G, et al. The role of regulatory T cell in nontypeable haemophilus influenzae-induced acute exacerbation of chronic obstructive pulmonary disease. Mediators Inflamm. 2018;2018:8387150. doi:10.1155/2018/8387150
   PubMed Web of Science ®Google Scholar
• Kim MS, Kim DJ, Na CH, Shin BSA. Study of the changes of T helper 17 cells and regulatory T cells in herpes zoster. Ann Dermatol. 2017;29(5):578–585. doi:10.5021/ad.2017.29.5.578
   PubMed Web of Science ®Google Scholar
• Betts RJ, Prabhu N, Ho AW, et al. Influenza A virus infection results in a robust, antigen-responsive, and widely disseminated Foxp3+ regulatory T cell response. J Virol. 2012;86(5):2817–2825. doi:10.1128/JVI.05685-11
   PubMed Web of Science ®Google Scholar
• Kudva A, Scheller EV, Robinson KM, et al. Influenza A inhibits Th17-mediated host defense against bacterial pneumonia in mice. J Immunol. 2011;186(3):1666–1674. doi:10.4049/jimmunol.1002194
   PubMed Web of Science ®Google Scholar
• Brereton CF, Sutton CE, Ross PJ, et al. Escherichia coli heat-labile enterotoxin promotes protective Th17 responses against infection by driving innate IL-1 and IL-23 production. J Immunol. 2011;186(10):5896–5906. doi:10.4049/jimmunol.1003789
   PubMed Web of Science ®Google Scholar
• Luo J, Zhang M, Yan B, Zhang K, Chen M, Deng S. Imbalance of Th17 and Treg in peripheral blood mononuclear cells of active tuberculosis patients. Braz J Infect Dis. 2017;21(2):155–161. doi:10.1016/j.bjid.2016.10.011
   PubMed Web of Science ®Google Scholar
• Nikitina IY, Panteleev AV, Kosmiadi GA, et al. Th1, Th17, and Th1Th17 lymphocytes during tuberculosis: th1 lymphocytes predominate and appear as low-differentiated CXCR3+CCR6+ cells in the blood and highly differentiated CXCR3±CCR6- cells in the lungs. J Immunol. 2018;200(6):2090–2103. doi:10.4049/jimmunol.1701424
   PubMed Web of Science ®Google Scholar
• Pai M, Denkinger CM, Kik SV, et al. Gamma interferon release assays for detection of Mycobacterium tuberculosis infection. Clin Microbiol Rev. 2014;27(1):3–20. doi:10.1128/CMR.00034-13
   PubMed Web of Science ®Google Scholar
• Li Q, Li J, Tian J, et al. IL-17 and IFN-γ production in peripheral blood following BCG vaccination and Mycobacterium tuberculosis infection in human. Eur Rev Med Pharmacol Sci. 2012;16(14):2029–2036.
   PubMed Web of Science ®Google Scholar
• Aung H, Toossi Z, McKenna SM, et al. Expression of transforming growth factor-beta but not tumor necrosis factor-alpha, interferon-gamma, and interleukin-4 in granulomatous lung lesions in tuberculosis. Tuber Lung Dis. 2000;80(2):61–67. doi:10.1054/tuld.2000.0235
   PubMedGoogle Scholar
• Wu M, Aung H, Hirsch CS, Toossi Z. Inhibition of Mycobacterium tuberculosis-induced signalling by transforming growth factor-β in human mononuclear phagocytes. Scand J Immunol. 2012;75(3):301–304. doi:10.1111/j.1365-3083.2011.02668.x
   PubMed Web of Science ®Google Scholar
• Albillos A, Lario M, Álvarez-mon M. Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance. J Hepatol. 2014;61(6):1385–1396. doi:10.1016/j.jhep.2014.08.010
   PubMed Web of Science ®Google Scholar
• Bentires-Alj M, Paez JG, David FS, et al. Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res. 2004;64(24):8816–8820. doi:10.1158/0008-5472.CAN-04-1923
   PubMed Web of Science ®Google Scholar
• Lee IO, Kim JH, Choi YJ, et al. Helicobacter pylori CagA phosphorylation status determines the gp130-activated SHP2/ERK and JAK/STAT signal transduction pathways in gastric epithelial cells. J Biol Chem. 2010;285(21):16042–16050. doi:10.1074/jbc.M110.111054
   PubMed Web of Science ®Google Scholar
• Neumann WL, Coss E, Rugge M, Genta RM. Autoimmune atrophic gastritis–pathogenesis, pathology and management. Nat Rev Gastroenterol Hepatol. 2013;10(9):529–541. doi:10.1038/nrgastro.2013.101
   PubMed Web of Science ®Google Scholar
• Shi WJ, Liu W, Zhou XY, Ye F, Zhang GX. Associations of Helicobacter pylori infection and cytotoxin-associated gene A status with autoimmune thyroid diseases: a meta-analysis. Thyroid. 2013;23(10):1294–1300. doi:10.1089/thy.2012.0630
   PubMed Web of Science ®Google Scholar
• Smyk DS, Koutsoumpas AL, Mytilinaiou MG, Rigopoulou EI, Sakkas LI, Bogdanos DP. Helicobacter pylori and autoimmune disease: cause or bystander. World J Gastroenterol. 2014;20(3):613–629. doi:10.3748/wjg.v20.i3.613
   PubMed Web of Science ®Google Scholar
• Miller WE, Mosialos G, Kieff E, Raab-Traub N. Epstein-Barr virus LMP1 induction of the epidermal growth factor receptor is mediated through a TRAF signaling pathway distinct from NF-kappaB activation. J Virol. 1997;71(1):586–594. doi:10.1128/JVI.71.1.586-594.1997
   PubMed Web of Science ®Google Scholar
• Dawson CW, Laverick L, Morris MA, Tramoutanis G, Young LS. Epstein-Barr virus-encoded LMP1 regulates epithelial cell motility and invasion via the ERK-MAPK pathway. J Virol. 2008;82(7):3654–3664. doi:10.1128/JVI.01888-07
   PubMed Web of Science ®Google Scholar
• Dawson CW, Tramountanis G, Eliopoulos AG, Young LS. Epstein-Barr virus latent membrane protein 1 (LMP1) activates the phosphatidylinositol 3-kinase/Akt pathway to promote cell survival and induce actin filament remodeling. J Biol Chem. 2003;278(6):3694–3704. doi:10.1074/jbc.M209840200
   PubMed Web of Science ®Google Scholar
• Vaysberg M, Lambert SL, Krams SM, Martinez OM. Activation of the JAK/STAT pathway in Epstein Barr virus+-associated posttransplant lymphoproliferative disease: role of interferon-gamma. Am J Transplant. 2009;9(10):2292–2302. doi:10.1111/j.1600-6143.2009.02781.x
   PubMed Web of Science ®Google Scholar
• Ando S, Kawada JI, Watanabe T, et al. Tofacitinib induces G1 cell-cycle arrest and inhibits tumor growth in Epstein-Barr virus-associated T and natural killer cell lymphoma cells. Oncotarget. 2016;7(47):76793–76805. doi:10.18632/oncotarget.12529
   PubMedGoogle Scholar
• Fujiwara S, Takei M. Epstein‐Barr virus and autoimmune diseases. Clin Exp Neuroimmunol. 2015;6:38–48. doi:10.1111/cen3.12263
   Google Scholar
• Shang B, Liu Y, Jiang SJ, Liu Y. Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis. Sci Rep. 2015;5(1):15179. doi:10.1038/srep15179
   PubMed Web of Science ®Google Scholar
• Ueki IF, Min-Oo G, Kalinowski A, et al. Respiratory virus-induced EGFR activation suppresses IRF1-dependent interferon λ and antiviral defense in airway epithelium. J Exp Med. 2013;210(10):1929–1936. doi:10.1084/jem.20121401
   PubMed Web of Science ®Google Scholar
• Alkharsah KR. VEGF upregulation in viral infections and its possible therapeutic implications. Int J Mol Sci. 2018;19(6):1642. doi:10.3390/ijms19061642
   PubMed Web of Science ®Google Scholar
• Soroceanu L, Akhavan A, Cobbs CS. Platelet-derived growth factor-alpha receptor activation is required for human cytomegalovirus infection. Nature. 2008;455(7211):391–395. doi:10.1038/nature07209
   PubMed Web of Science ®Google Scholar
• DuShane JK, Maginnis MS. Human DNA virus exploitation of the MAPK-ERK cascade. Int J Mol Sci. 2019;20(14):3427. doi:10.3390/ijms20143427
   PubMed Web of Science ®Google Scholar
• Benn J, Schneider RJ. Hepatitis B virus HBx protein activates Ras-GTP complex formation and establishes a Ras, Raf, MAP kinase signaling cascade. Proc Natl Acad Sci U S A. 1994;91(22):10350–10354. doi:10.1073/pnas.91.22.10350
   PubMed Web of Science ®Google Scholar
• Klein NP, Schneider RJ. Activation of Src family kinases by hepatitis B virus HBx protein and coupled signaling to Ras. Mol Cell Biol. 1997;17(11):6427–6436. doi:10.1128/mcb.17.11.6427
   PubMed Web of Science ®Google Scholar
• Tran TTP, Eichholz K, Amelio P, et al. Humoral immune response to adenovirus induce tolerogenic bystander dendritic cells that promote generation of regulatory T cells. PLoS Pathog. 2018;14(8):e1007127. doi:10.1371/journal.ppat.1007127
   PubMed Web of Science ®Google Scholar
• Gaido CM, Granland C, Laing IA, et al. T-cell responses against rhinovirus species A and C in asthmatic and healthy children. Immun Inflamm Dis. 2018;6(1):143–153. doi:10.1002/iid3.206
   PubMed Web of Science ®Google Scholar
• Tovar-Salazar A, Weinberg A. Understanding the mechanism of action of cytomegalovirus-induced regulatory T cells. Virology. 2020;547:1–6. doi:10.1016/j.virol.2020.05.001
   PubMed Web of Science ®Google Scholar
• Jayaratne HE, Wijeratne D, Fernando S, et al. Regulatory T-cells in acute dengue viral infection. Immunology. 2018;154(1):89–97. doi:10.1111/imm.12863
   PubMed Web of Science ®Google Scholar
• Benson A, Murray S, Divakar P, et al. Microbial infection-induced expansion of effector T cells overcomes the suppressive effects of regulatory T cells via an IL-2 deprivation mechanism. J Immunol. 2012;188(2):800–810. doi:10.4049/jimmunol.1100769
   PubMed Web of Science ®Google Scholar
• Fleming SB. Viral inhibition of the IFN-induced JAK/STAT signalling pathway: development of live attenuated vaccines by mutation of viral-encoded IFN-antagonists. Vaccines (Basel). 2016;4(3):23. doi:10.3390/vaccines4030023
   PubMed Web of Science ®Google Scholar
• Kak G, Raza M, Tiwari BK. Interferon-gamma (IFN-γ): exploring its implications in infectious diseases. Biomol Concepts. 2018;9(1):64–79. doi:10.1515/bmc-2018-0007
   PubMedGoogle Scholar
• Gerada C, Campbell TM, Kennedy JJ, et al. Manipulation of the innate immune response by varicella zoster virus. Front Immunol. 2020;11:1. doi:10.3389/fimmu.2020.00001
   PubMed Web of Science ®Google Scholar
• Beekhuizen H, van de Gevel JS. Gamma interferon confers resistance to infection with Staphylococcus aureus in human vascular endothelial cells by cooperative proinflammatory and enhanced intrinsic antibacterial activities. Infect Immun. 2007;75(12):5615–5626. doi:10.1128/IAI.00530-07
   PubMed Web of Science ®Google Scholar
• Norkina O, Dolganiuc A, Shapiro T, Kodys K, Mandrekar P, Szabo G. Acute alcohol activates STAT3, AP-1, and Sp-1 transcription factors via the family of Src kinases to promote IL-10 production in human monocytes. J Leukoc Biol. 2007;82(3):752–762. doi:10.1189/jlb.0207099
   PubMed Web of Science ®Google Scholar
• Psaltopoulou T, Sergentanis TN, Ntanasis-Stathopoulos I, Tzanninis IG, Tsilimigras DI, Dimopoulos MA. Alcohol consumption and risk of hematological malignancies: a meta-analysis of prospective studies. Int J Cancer. 2018;143(3):486–495. doi:10.1002/ijc.31330
   PubMed Web of Science ®Google Scholar
• Rasouli B, Ahlbom A, Andersson T, et al. Alcohol consumption is associated with reduced risk of type 2 diabetes and autoimmune diabetes in adults: results from the Nord-Trøndelag health study. Diabet Med. 2013;30(1):56–64. doi:10.1111/j.1464-5491.2012.03713.x
   PubMed Web of Science ®Google Scholar
• Zeng C, Shi X, Zhang B, et al. The imbalance of Th17/Th1/Tregs in patients with type 2 diabetes: relationship with metabolic factors and complications. J Mol Med (Berl). 2012;90(2):175–186. doi:10.1007/s00109-011-0816-5
   PubMed Web of Science ®Google Scholar
• Farag AGA, Samaka R, Elshafey EN, Shehata WA, El Sherbiny EG, Hammam MA. Immunohistochemical study of janus kinase 1/signal transducer and activator of transcription 3 in psoriasis vulgaris. Clin Cosmet Investig Dermatol. 2019;12:497–508. doi:10.2147/CCID.S202835
   PubMed Web of Science ®Google Scholar
• Gruber CN, Calis JJA, Buta S, et al. Complex autoinflammatory syndrome unveils fundamental principles of JAK1 kinase transcriptional and biochemical function. Immunity. 2020;53(3):672–684.e11. doi:10.1016/j.immuni.2020.07.006
   PubMed Web of Science ®Google Scholar
• Del Bel KL, Ragotte RJ, Saferali A, et al. JAK1 gain-of-function causes an autosomal dominant immune dysregulatory and hypereosinophilic syndrome. J Allergy Clin Immunol. 2017;139(6):2016–2020.e5. doi:10.1016/j.jaci.2016.12.957
   PubMed Web of Science ®Google Scholar
• Arulogun SO, Choong HL, Taylor D, et al. JAK1 somatic mutation in a myeloproliferative neoplasm. Haematologica. 2017;102(8):e324–e327. doi:10.3324/haematol.2017.170266
   PubMed Web of Science ®Google Scholar
• Albacker LA, Wu J, Smith P, et al. Loss of function JAK1 mutations occur at high frequency in cancers with microsatellite instability and are suggestive of immune evasion. PLoS One. 2017;12(11):e0176181. doi:10.1371/journal.pone.0176181
   PubMed Web of Science ®Google Scholar
• Ren Y, Zhang Y, Liu RZ, et al. JAK1 truncating mutations in gynecologic cancer define new role of cancer-associated protein tyrosine kinase aberrations. Sci Rep. 2013;3(1):3042. doi:10.1038/srep03042
   PubMedGoogle Scholar
• Hu J, Wu X, Huang P, Teng F, Wang Y, Xue F. The proportion and prognostic significance of T-regulatory cells in patients with gynecological cancers: a systematic review and meta-analysis. J Cancer. 2020;11(11):3340–3348. doi:10.7150/jca.42472
   PubMed Web of Science ®Google Scholar
• Zhang X, Kelaria S, Kerstetter J, Wang J. The functional and prognostic implications of regulatory T cells in colorectal carcinoma. J Gastrointest Oncol. 2015;6(3):307–313. doi:10.3978/j.issn.2078-6891.2015.017
   PubMed Web of Science ®Google Scholar
• Liu X, Zhang Z, Zhao G. Recent advances in the study of regulatory T cells in gastric cancer. Int Immunopharmacol. 2019;73:560–567. doi:10.1016/j.intimp.2019.05.009
   PubMed Web of Science ®Google Scholar
• Dai J, Lu Y, Roca H, et al. Immune mediators in the tumor microenvironment of prostate cancer. Chin J Cancer. 2017;36(1):29. doi:10.1186/s40880-017-0198-3
   PubMedGoogle Scholar
• Xu P, Fan W, Zhang Z, et al. The clinicopathological and prognostic implications of FoxP3+ regulatory T cells in patients with colorectal cancer: a meta-analysis. Front Physiol. 2017;8:950. doi:10.3389/fphys.2017.00950
   PubMed Web of Science ®Google Scholar
• Paniagua RT, Sharpe O, Ho PP, et al. Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. J Clin Invest. 2006;116(10):2633–2642. doi:10.1172/JCI28546
   PubMed Web of Science ®Google Scholar
• Eklund KK, Joensuu H. Treatment of rheumatoid arthritis with imatinib mesylate: clinical improvement in three refractory cases [published correction appears in Ann Med. 2003;35(8):640]. Ann Med. 2003;35(5):362–367. doi:10.1080/07853890310001339
   PubMed Web of Science ®Google Scholar
• Eklund KK, Remitz A, Kautiainen H, Reitamo S, Leirisalo-Repo M. Three months treatment of active spondyloarthritis with imatinib mesylate: an open-label pilot study with six patients. Rheumatology (Oxford). 2006;45(12):1573–1575. doi:10.1093/rheumatology/kel365
   PubMed Web of Science ®Google Scholar
• Kuang YH, Lu Y, Liu YK, et al. Topical Sunitinib ointment alleviates Psoriasis-like inflammation by inhibiting the proliferation and apoptosis of keratinocytes. Eur J Pharmacol. 2018;824:57–63. doi:10.1016/j.ejphar.2018.01.048
   PubMed Web of Science ®Google Scholar
• Ozgen M, Koca SS, Karatas A, et al. Lapatinib ameliorates experimental arthritis in rats. Inflammation. 2015;38(1):252–259. doi:10.1007/s10753-014-0028-6
   PubMed Web of Science ®Google Scholar
• Gore J, Craven KE, Wilson JL, et al. TCGA data and patient-derived orthotopic xenografts highlight pancreatic cancer-associated angiogenesis. Oncotarget. 2015;6(10):7504–7521. doi:10.18632/oncotarget.3233
   PubMedGoogle Scholar
• Koblish HK, Hansbury M, Wang L-CS, et al. Novel immunotherapeutic activity of JAK and PI3Kδ inhibitors in a model of pancreatic cancer [abstract]. Cancer Res. 2015;75:1336. doi:10.1158/1538-7445.am2015-1336
   Web of Science ®Google Scholar
• Zhu Z, Aref AR, Cohoon TJ, et al. Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit. Cancer Discov. 2014;4(4):452–465. doi:10.1158/2159-8290.CD-13-0646
   PubMed Web of Science ®Google Scholar
• Barbie DA, Spira A, Kelly K, et al. Phase 1B study of momelotinib combined with trametinib in metastatic, kirsten rat sarcoma viral oncogene homolog-mutated non-small-cell lung cancer after platinum-based chemotherapy treatment failure. Clin Lung Cancer. 2018;19(6):e853–e859. doi:10.1016/j.cllc.2018.07.004
   PubMed Web of Science ®Google Scholar
• Ng K, Hendifar A, Starodub A, et al. Phase 1 dose-escalation study of momelotinib, a Janus kinase 1/2 inhibitor, combined with gemcitabine and nab-paclitaxel in patients with previously untreated metastatic pancreatic ductal adenocarcinoma. Invest New Drugs. 2019;37(1):159–165. doi:10.1007/s10637-018-0650-5
   PubMed Web of Science ®Google Scholar
• Fogelman D, Cubillo A, García-Alfonso P, et al. Randomized, double-blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer. Cancer Med. 2018;7(11):5382–5393. doi:10.1002/cam4.1703
   PubMed Web of Science ®Google Scholar
• Hurwitz HI, Uppal N, Wagner SA, et al. Randomized, double-blind, phase II study of ruxolitinib or placebo in combination with capecitabine in patients with metastatic pancreatic cancer for whom therapy with gemcitabine has failed. J Clin Oncol. 2015;33(34):4039–4047. doi:10.1200/JCO.2015.61.4578
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Van Cutsem E, Bendell J, et al. Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies. Invest New Drugs. 2018;36(4):683–695. doi:10.1007/s10637-018-0580-2
   PubMed Web of Science ®Google Scholar